文献速递炎症性肠病

克罗恩病成人处方阿片类药物使用高于一般人群:瑞典2006-2021年全国队列研究

Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006-2021.
PubMed 文献 · Aliment Pharmacol Ther · 2025-06-01

这项瑞典全国登记研究纳入10527例新发克罗恩病患者和96123名匹配对照,以及32306例现患患者和289516名对照。新发患者诊断前2年阿片类药物配药率为26.2%对12.6%,诊断后13-36个月仍高达26.5%对11.7%。现患队列中弱阿片类药物使用下降,但阿片类药物平均日剂量仅在克罗恩病患者中大幅下降。

要点

  • 新发克罗恩病患者诊断前2年阿片类药物配药率为对照的约两倍(26.2%对12.6%)。
  • 诊断后13-36个月配药率仍高(26.5%对11.7%),诊断前后达三至四倍。
  • 现患队列中弱阿片类药物使用大幅下降,可能解释近期阿片消费下降。

核心结论

  • 新发克罗恩病成人诊断前2年阿片类药物配药率为对照的两倍,诊断前后达三至四倍,并持续高至3-5年。
  • 弱阿片类药物使用减少可能解释克罗恩病患者近期阿片消费下降。

研究设计与样本

  • 瑞典全国登记研究,纳入≥18岁新发(2008-2019)或现患(2008-2021)克罗恩病患者及最多10名无炎症性肠病的个体匹配对照。

主要发现

  • 新发队列10527例患者和96123名对照,诊断前2年阿片配药率26.2%对12.6%。
  • 诊断后13-36个月配药率26.5%对11.7%。
  • 现患队列32306例患者和289516名对照,弱阿片使用在克罗恩病患者中从16.0%降至6.0%,对照从8.0%降至3.0%。
  • 阿片平均日剂量仅在克罗恩病患者中于2008至2021年间大幅下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Population-based data on prescribed opioid use among adults with Crohn's disease (CD) remain limited. METHODS: This nationwide register-based study included individuals ≥ 18 years with incident (2008-2019) or prevalent (2008-2021) CD and up to 10 individually matched reference individuals without inflammatory bowel disease. We categorised opioid dispensations as weak (e.g., tramadol) or strong (e.g., oxycodone). We calculated the prevalence of ≥ 1 dispensation and mean daily doses (MDD) of opioids per 6 month period from 2 years before until 5 years following CD diagnosis (for incident cohort) and annual dispensation and MDD of opioids (for prevalent cohort). RESULTS: Among 10,527 patients with incident CD and 96,123 references, opioid dispensations were two-fold among patients 2 years before diagnosis (26.2% vs. 12.6%) and remained high 13-36 months after diagnosis (26.5% vs. 11.7%). In the prevalent cohort (32,306 patients and 289,516 reference individuals), there was a declining trend in the use of dispensed opioids. During observation, the use of weak opioids decreased substantially among individuals with CD (16.0% vs. 6.0%) and reference individuals (8.0% vs. 3.0%). However, opioid MDD only decreased substantially among those with CD between 2008 and 2021. CONCLUSION: Adults with incident CD had a two-fold higher use of dispensed opioids than references 2 years before diagnosis, which peaked at three- and four-fold higher use around diagnosis and remained high for 3-5 years. The decreased use of weak opioids might explain the recent decline in opioid consumption among patients with CD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Osooli M, Voghera S, Bruze G, et al. Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006-2021. Aliment Pharmacol Ther. 2025. PMID: 40450700. doi:10.1111/apt.70203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。